4 registrations that name senna as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
Phase
6US sites across 5 states
1
2 to 4
5 to 19
20 or more
All 4 registrations
RecruitingNCT04113382
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
Phase 1 and 2
Ferring Pharmaceuticals
About 39 people
Started Jun 23, 2022
In plain words A Phase 1 and 2 study of senna in people 12 months to 8, run by Ferring Pharmaceuticals. It plans to enroll about 39 people at 4 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 12 months to 8. Conditions: Bowel Preparation.
Male or female, aged 12 months to <9 years being scheduled to undergo elective colonoscopy.
Weight ≥10 kg (≥22 lbs).
Participants must have had regular spontaneous bowel movements (SBM) weekly for 1 month prior to the colonoscopy.
Written informed consent (by parent(s)/ caregiver(s)/ guardian(s)) and assent (if applicable) obtained at screening.
The exclusion criteria are on the listing.
What it tests, as registered
CLENPIQ; MIRALAX; SENNA
Registered summary
Bowel preparation for pediatric colonoscopy.
Where, as registered
4 US sites in 3 states.
RecruitingNCT06825260
PEG3350 vs Senna After Urogyn Surgery
Phase 4
St. Joseph's Health, New York
About 254 people
Started Apr 23, 2025
In plain words A Phase 4 study of senna in female participants 18 and older, run by St. Joseph's Health, New York. It plans to enroll about 254 people at 1 US site.
The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after… The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06335797
Optimization of Postoperative Bowel Habits
No phase
Wake Forest University Health Sciences
About 88 people
Started Oct 16, 2024
In plain words A study of senna in female participants 18 and older, run by Wake Forest University Health Sciences. It plans to enroll about 88 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Constipation.
Women ages 18 and older scheduled to undergo vaginal pelvic organ prolapse repair
The exclusion criteria are on the listing.
What it tests, as registered
Senna Tab; Dulcolax Suppositories
Registered summary
Project is a trial, in which women undergoing vaginal surgery for pelvic organ prolapse will be randomized 1:1 to a postoperative bowel regimen of either oral senna or rectal bisacodyl suppository.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07604025
Senna vs. Polyethylene Glycol 3350 for the Treatment of Retentive Encopresis in Children
Early phase 1
Shaare Zedek Medical Center
About 80 people
Starts Jul 1, 2026 (estimated)
In plain words An early phase 1 study of senna in people 4 to 17, run by Shaare Zedek Medical Center. It plans to enroll about 80 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 17. Conditions: Encopresis With Constipation and Overflow Incontinence.
Children aged 4 to 18 years.
Diagnosis of functional constipation according to Rome IV criteria.
Fecal incontinence occurring ≥4 times per week.
Treatment-naïve or treatment-experienced (i.e., any of the following treatments in the past: PEG, senna, bisacodyl and rectal disimpaction) patients.
The exclusion criteria are on the listing.
What it tests, as registered
PEG 3350; Senna
Registered summary
The goal of this clinical trial is to learn which treatment is more effective for children with functional constipation (FC) and fecal incontinence (FI), also called retentive encopresis. Functional constipation is common in children and can cause pain, embarrassment, social stress, and repeated medical visits. One of the hardest symptoms to treat is fecal incontinence. Two common treatments are polyethylene glycol 3350 (PEG), an osmotic laxative, and Senna, a plant-based stimulant laxative. The full summary is on the listing.